Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)

ClinicalTrials.gov ID: NCT01581203

Public ClinicalTrials.gov record NCT01581203. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Study With Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects With Chronic Hepatitis C Genotype 1b Infection

Study identification

NCT ID
NCT01581203
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
748 participants

Conditions and interventions

Interventions

  • Asunaprevir (ASV) Drug
  • Daclatasvir (DCV) Drug
  • Pegylated-interferon alfa 2a (PegIFN) Drug
  • Ribavirin (RBV) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2012
Primary completion
Sep 30, 2013
Completion
Aug 31, 2014
Last update posted
Oct 8, 2015

2012 – 2014

United States locations

U.S. sites
18
U.S. states
12
U.S. cities
17
Facility City State ZIP Site status
The Health Care Authority For Baptist Health Montgomery Alabama 36116
Scripps Clinic La Jolla California 92037
Scpmg/ Kaiser Permanente Los Angeles Medical Center Los Angeles California 90027
University Of Colorado Denver And Hospital Aurora Colorado 80045
Uf Hepatology Research At Ctrb Gainesville Florida 32610
Johns Hopkins Medical Institutions Lutherville Maryland 21093
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
Henry Ford Health System Detroit Michigan 48202
Washington University School Of Medicine St Louis Missouri 63110
North Shore-Long Island Jewish Health System Manhasset New York 11030
Weill Cornell Medical College New York New York 10021
University Of North Carolina At Chapel Hill School Of Med Chapel Hill North Carolina 27599
Carolinas Medical Center Charlotte North Carolina 28204
Duke University Medical Center Durham North Carolina 27710
Baylor College Of Medicine Houston Texas 77030
Vamc Houston Texas 77030
Alamo Medical Research San Antonio Texas 78215
Dean Clinic Madison Wisconsin 53715

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 98 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01581203, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 8, 2015 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01581203 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →